Modular Medical Finalizes $2.9M Direct Offering to Fund Operations and Pivot Pump Commercialization

summarizeSummary

Modular Medical, Inc. has finalized a registered direct offering of 750,000 shares at $4.50 each, raising approximately $2.9 million in net proceeds to address its liquidity needs and support the commercial launch of its newly FDA-cleared Pivot insulin pump.

check_boxKey Events

• Direct Offering Finalized

  Modular Medical, Inc. is offering 750,000 shares of common stock at an offering price of $4.50 per share, generating approximately $2.9 million in net proceeds after deducting placement agent fees and estimated offering expenses. This formalizes the offering that was priced on April 19, 2026.

• Addresses Immediate Liquidity Needs

  The capital raise is crucial for the company, which previously reported an immediate liquidity crisis and substantial doubt about its ability to continue as a going concern. The net proceeds are intended for general corporate purposes, including working capital and capital expenditures.

• Supports Pivot Pump Commercialization

  This funding directly supports the commercial launch of the company's Pivot tubeless insulin patch pump, which received FDA 510(k) clearance on April 9, 2026, a significant regulatory milestone.

• Significant Dilution and Discounted Pricing

  The offering represents a dilution of approximately 16.09% of the company's outstanding shares. The offering price of $4.50 per share is at a discount compared to the last reported sale price of $5.86 on April 17, 2026, and today's price of $5.16.

auto_awesomeAnalysis

Modular Medical, Inc. has finalized a registered direct offering, securing approximately $2.9 million in net proceeds. This capital raise is critical for the company, which previously disclosed an immediate liquidity crisis and substantial doubt about its ability to continue as a going concern. While the offering is dilutive, representing over 16% of outstanding shares and priced at a discount to recent market levels, it provides essential funding to support general corporate purposes, including the commercial launch of its newly FDA-cleared Pivot insulin pump. However, the company projects this funding will only extend its operational runway for approximately four months, indicating a continued need for future capital raises.